Milbemycin Oxime (A3 and A4), Praziquantel

Form: Tablet · Pack size: PK 48

Dogs

Milprazon CHEWABLE 2.5 mg/25 mg film-coated Tablets for Small Dogs and Puppies Weighing At Least 0.5 kg. Do not use in puppies of less than 2 weeks of age and/or weighing less than 0.5 kg. Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

• Legal category: POM-V
• Marketing authorisation holder: KRKA, d.d., Novo mesto Šmarješka cesta 6 8501 Novo mesto Slovenia Further information Pharmacotherapeutic group: Endectocides, Macrocyclic lactones, milbemycin, combinations. ATCvet code: QP54AB51 Pharmacodynamic Properties Milbemycin oxime belongs to the group of macrocyclic lactones, isolated from the fermentation of Streptomyces hygroscopicus var. aureolacrimosus. It is active against mites, against larval and adult stages of nematodes as well as against larvae of Dirofilaria immitis. The activity of milbemycin is related to its action on invertebrate neurotransmission: Milbemycin oxime, like avermectins and other milbemycins, increases nematode and insect membrane permeability to chloride ions via glutamate-gated chloride ion channels (related to vertebrate GABAA and glycine receptors). This leads to hyperpolarisation of the neuromuscular membrane and flaccid paralysis and death of the parasite. Praziquantel is an acylated pyrazino-isoquinoline derivative. Praziquantel is active against cestodes and trematodes. It modifies the permeability for calcium (influx of Ca2+) in the membranes of the parasite inducing an imbalance in the membrane structures, leading to membrane depolarisation and almost instantaneous contraction of the musculature (tetany), rapid vacuolization of the syncytial tegument and subsequent tegumental disintegration (blebbing), resulting in easier expulsion from the gastrointestinal tract or death of the parasite. Pharmacokinectic particulars After oral administration of praziquantel in the dog, after a small amount of food, peak serum levels of parent are rapidly attained (Tmax approximately 0.25-2.5 hours) and decline quickly (t1/2 approximately 1 hour); there is a substantial hepatic first-pass effect, with very rapid and almost complete hepatic biotransformation, principally to monohydroxylated (also some di- and tri-hydroxylated) derivatives, which are mostly glucuronide and/or sulfate conjugated before excretion. Plasma binding is about 80%. Excretion is fast and complete (about 90% in 2 days); the principal route of elimination is renal. After oral administration of milbemycin oxime in dogs, after a small amount of food, peak plasma levels occur at about 0.75-3.5 hours, and decline with a half-life of the unmetabolised milbemycin oxime of 1-4 days. Bioavailability is about 80%.
• MA number: Milprazon CHEWABLE Tablets for Small Dogs and Puppies: Vm 01656/5082 Milprazon CHEWABLE Tablets for Dogs: Vm 01656/5083

The information on this page is provided for general guidance only and does not replace the advice of a qualified veterinary surgeon. Always follow the directions provided on the product packaging and by your veterinary practice. If your animal's condition does not improve, worsens, or any side effects occur, contact your veterinary surgeon immediately.